319 related articles for article (PubMed ID: 16843835)
1. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Honer M; Hengerer B; Blagoev M; Hintermann S; Waldmeier P; Schubiger PA; Ametamey SM
Nucl Med Biol; 2006 Jul; 33(5):607-14. PubMed ID: 16843835
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
4. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
5. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
[TBL] [Abstract][Full Text] [Related]
6. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
7. Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Yee RE; Irwin I; Milonas C; Stout DB; Huang SC; Shoghi-Jadid K; Satyamurthy N; Delanney LE; Togasaki DM; Farahani KF; Delfani K; Janson AM; Phelps ME; Langston JW; Barrio JR
Mov Disord; 2001 Sep; 16(5):838-48. PubMed ID: 11746613
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.
Huang WS; Ma KH; Chou YH; Chen CY; Liu RS; Liu JC
Nucl Med Commun; 2003 Jan; 24(1):77-83. PubMed ID: 12501023
[TBL] [Abstract][Full Text] [Related]
9. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
10. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.
Masilamoni G; Votaw J; Howell L; Villalba RM; Goodman M; Voll RJ; Stehouwer J; Wichmann T; Smith Y
Exp Neurol; 2010 Dec; 226(2):265-73. PubMed ID: 20832405
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements.
Zoghbi SS; Shetty HU; Ichise M; Fujita M; Imaizumi M; Liow JS; Shah J; Musachio JL; Pike VW; Innis RB
J Nucl Med; 2006 Mar; 47(3):520-7. PubMed ID: 16513622
[TBL] [Abstract][Full Text] [Related]
13. [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study.
Kuten J; Linevitz A; Lerman H; Freedman N; Kestenbaum M; Shiner T; Giladi N; Even-Sapir E
J Integr Neurosci; 2020 Sep; 19(3):489-494. PubMed ID: 33070528
[TBL] [Abstract][Full Text] [Related]
14. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
[TBL] [Abstract][Full Text] [Related]
15. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
[TBL] [Abstract][Full Text] [Related]
16. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
Piccini P; Turjanski N; Brooks DJ
J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
[TBL] [Abstract][Full Text] [Related]
17. In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.
Walker MD; Dinelle K; Kornelsen R; McCormick S; Mah C; Holden JE; Farrer MJ; Stoessl AJ; Sossi V
J Cereb Blood Flow Metab; 2013 Jan; 33(1):59-66. PubMed ID: 22929441
[TBL] [Abstract][Full Text] [Related]
18. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two methods for the analysis of [18F]6-fluoro-L-m-tyrosine PET data.
Eberling JL; Pivirotto P; Bringas J; Bankiewicz KS
Neuroimage; 2004 Sep; 23(1):358-63. PubMed ID: 15325383
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Biological Evaluation of [
Cao S; Tang J; Liu C; Fang Y; Ji L; Xu Y; Chen Z
Mol Imaging Biol; 2021 Oct; 23(5):733-744. PubMed ID: 33851345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
